Schlossmacher Lab

Michael Schlossmacher profile picture

Contact Information

Michael Schlossmacher, MD, DABPN, FRCPC
613-562-5800 x 8123

Administrative Assistant:
Charlotte McCusker
613-562-5800 x 8123

What We Do

Since 2000, I have pursued work as a physician-scientist focusing on Parkinson disease (PD), Lewy body dementia (DLB) and multiple system atrophy (MSA). In 2007, I opened my laboratory at the OHRI. Over the last 7 years my team has focused on: (i) modeling of the pathogenesis of PD and DLB in mouse models; (ii) validation of drug targets to lower alpha-synuclein concentrations; and (iii) biomarker exploration in PD, DLB and MSA based on alpha-synuclein metabolism.

Selected Publications

Cullen V* et al. Acid beta-glucosidase mutations linked to Gaucher disease, Parkinson's and Lewy body dementia dysregulate a-synuclein in vivo. Ann Neurol 2011;69:940-53 *This paper was awarded the editor's ‘Annals of Neurology Prize' in 2012 

Hakimi M et al. Parkinson's-linked LRRK2 is expressed in immune cells and upregulated after the recognition of microbial structures. J Neural Transm 2011;118:795-808  

Mollenhauer B* et al. Cerebrospinal fluid values of a-synuclein and tau in patients presenting with parkinsonism. Lancet Neurol 2011;10:230-40 and Lancet Neurol 2011;10:681-3;
*See also the opinion piece published in: Lancet Neurol 2011;10(3):203-5

Kitada T, Tomlinson JJ et al. Considerations regarding the etiology and treatment of recessive versus idiopathic Parkinson disease. Curr Treat Opt Neurol 2012;14:230-40

Cullen V* et al. Cathepsin D expression affects the processing, aggregation and toxicity of a-synuclein in vivo. Mol Brain 2009;2:5(1-17) 
*This paper was awarded the editor's ‘Molecular Brain Award' in 2012

Meet the Schlossmacher Lab